Brought to you by 
Janssen Biotech teams up with Vedanta Biosciences; deal expanded; Vedanta Regains Full Rights
01 Aug 2022
Executive Summary
Johnson & Johnson’s Janssen Biotech Inc. has allied with Vedanta Biosciences (focused on mucosal immunology) on the development of therapeutics that modulate pathways that interact between the human microbiome and immune system. As part of the deal, J&J's venture arm made an undisclosed equity investment in Vedanta.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen Biotech teams up with Vedanta Biosciences; deal expanded; Vedanta Regains Full Rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice